Viewpoints

With the pharmaceutical industry being in a current state of unrest in light of the recent spate of mergers, acquisitions, job cuts, divestments, patent expiries, and so on, we wanted to know how you felt about all these changes that will have directly or indirectly affected you.

From healthcare to corruption to life expectancy, here's what we can learn from the past decade.

Directors and staff miss the mark when it comes to following procedures.

Dumbed-down presentations and poor speaker selections are destroying a valuable industry tool.

With so many healthcare and pharmacy websites, consumers could use the agency's nod of support.

Blame it on cafeteria gossip, outdated procedures, and major miscommunication.

It's the end of the year already and I hope you are looking forward to the festive period and the opportunity to wind down and spend some quality time with family and friends.

New tests solve one issue, but cheaper plastic and new stoppers cause problems.

While Congress debates hundreds of healthcare plan proposals, perhaps we, the public, can get in the game too.

New standards may overlook critical qualification needs.

November is finally upon us and the days are getting colder and shorter.

AAPS President offers hope and solutions for the industry's challenging future.

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.

The nation's healtcare system needs an overhaul, but it has to be done right.

Like life, the workplace also can have many surprises.

Well, the summer's well and truly behind us and Madrid beckons for this year's CPhI Worldwide.

Thanks to their keen observations, these auditors reveal the true culprits of deviations.

After years of promomting QbD concepts, FDA's ready to take action on nonconformers.

Personalized medicine and integrated healthcare delivery require new business and pricing models. This article contains bonus online-exclusive material.

Merger, union, alliance, partnership, collaboration: five words that ultimately suggest the strengthening of something.

Big Pharma entered biotech too late. That same mistake can be avoided in personalized medicine.

Individuals and companies at the top seem to have no problem short-circuiting their success.

An ounce of contamination usually leads to a mountain of investigation.

While regulators begin to address nano-based drugs, industry should get its risk data ready.

Some GMP agents seem to find a way to squander time, money, and common sense.

Is it good policy to pay for bad behavior?

Biopharmaceutical companies generally try to avoid paying royalties on novel technologies, including novel expression systems, in part because of the inability to predict revenue flow after a product is commercialized.

Patents are an important tool for protecting innovative products, uses or processes intended for commercialization.

The world's top 50 pharmaceutical companies accounted for prescription drug sales of $558 billion (413 billion euro) in 2008.

Are manufacturers ready to deal with the economic and logistical challenges that accompany tailored therapeutics?